Formulation, Characterization, and Stability of Protein Drugs: Case Histories, Vol. 9
Leading scientists offer detailed profiles of ten protein drugs currently in development. The case histories of these important new compounds are described from the perspective of their formulation, characterization, and stability. This ready reference also features recent data and an abundance of previously unpublished information. The in-depth coverage includes a highly useful compendium of degradation sites occurring in over 70 proteins. An invaluable aid in the rapid identification of...
Search in google:
Leading scientists offer detailed profiles of ten protein drugs currently in development. The case histories of these important new compounds are described from the perspective of their formulation, characterization, and stability. This ready reference also features recent data and an abundance of previously unpublished information. The in-depth coverage includes a highly useful compendium of degradation sites occurring in over 70 proteins. An invaluable aid in the rapid identification of potential `hot spots' in proteins, this accessible compilation allows for inspection of the protein's primary structure and preparation of a hydroflex plot. Booknews Provides practical approaches and examples for the design of formulations for therapeutic proteins, primarily those already available on the market or in various stages of clinical testing. The first chapter compiles information on degradation of some 70 proteins from the work of many laboratories. The remaining chapters are devoted to the stability and formulation of individual proteins, including basic fibroblasts, acidic fibroblasts, growth factor-Beta1, recombinant human relaxin, interferon-B- 1b (Betaseron), Neupogen (Filgrastim), LEUKINE, an antifibrin monoclonal antibody radiopharmaceutical, TP40, and recombinant human deoxyribonuclease I [Pulmozyme (Dornase Alpha)]. Annotation c. by Book News, Inc., Portland, Or.
Ch. 1A Compendium and Hydropathy/Flexibility Analysis of Common Reactive Sites in Proteins: Reactivity at Asn, Asp, Gln, and Met Motifs in Neutral pH SolutionCh. 2Characterization, Stability, and Formulations of Basic Fibroblast Growth FactorCh. 3The Characterization, Stabilization, and Formulation of Acidic Fibroblast Growth FactorCh. 4Stability, Characterization, Formulation, and Delivery System Development for Transforming Growth Factor-Beta[subscript 1]Ch. 5Stability and Characterization of Recombinant Human RelaxinCh. 6Interferon-[beta]-1b (Betaseron): A Model for Hydrophobic Therapeutic ProteinsCh. 7Characterization, Formulation, and Stability of Neupogen (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating FactorCh. 8Development and Shelf-Life Determination of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (LEUKINE, GM-CSF)Ch. 9Formulation Development of an Antifibrin Monoclonal Antibody RadiopharmaceuticalCh. 10Biophysical Characterization and Formulation of TP40: A Chimeric Protein that Requires a pH-Dependent Conformational Change for Its Biological ActivityCh. 11Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme (Dornase Alpha)]Index
\ BooknewsProvides practical approaches and examples for the design of formulations for therapeutic proteins, primarily those already available on the market or in various stages of clinical testing. The first chapter compiles information on degradation of some 70 proteins from the work of many laboratories. The remaining chapters are devoted to the stability and formulation of individual proteins, including basic fibroblasts, acidic fibroblasts, growth factor-Beta1, recombinant human relaxin, interferon-B- 1b (Betaseron), Neupogen (Filgrastim), LEUKINE, an antifibrin monoclonal antibody radiopharmaceutical, TP40, and recombinant human deoxyribonuclease I [Pulmozyme (Dornase Alpha)]. Annotation c. by Book News, Inc., Portland, Or.\ \
